Carbohydrate-functionalized nanovaccines preserve HIV-1 antigen stability and activate antigen presenting cells

Journal of Biomaterials Science, Polymer Edition

Volumn 25, Issue 13, 2014, Pages 1387-1406

  Vela Ramirez, J E ^a   Roychoudhury, R ^b   Habte, H H ^c,d   Cho, M W ^c   Pohl, N L B ^b   Narasimhan, B ^a  

^a Iowa State University   (United States)

^b INDIANA UNIVERSITY   (United States)

^c IOWA STATE UNIVERSITY   (United States)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

carbohydrates; dendritic cells; HIV antigen; nanoparticles; nanovaccines; polyanhydrides; targeting

Indexed keywords

CARBOHYDRATES; CELLS; CHEMICAL ACTIVATION; NANOPARTICLES; PATHOGENS;

ANTIGEN PRESENTING CELLS; DENDRITIC CELLS; DENDRITIC CELLS (DCS); FUNCTIONALIZED NANOPARTICLES; NANOVACCINES; POLYANHYDRIDES; POLYMERIC NANOPARTICLES; TARGETING;

ANTIGENS;

ANTIGEN; CARBOHYDRATE; CARBOXYMETHYL ALPHA MANNOPYRANOSYL (1,2) D MANNOPYRANOSIDE; CD206 ANTIGEN; CD40 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS 1 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 6; NANOPARTICLE; NANOVACCINE; POLYANHYDRIDE; POLYANHYDRIDE NANOPARTICLE; PYRANOSIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN-6, MOUSE; LECTIN; MANNOSE BINDING LECTIN; MANNOSE RECEPTOR; RECOMBINANT VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ANTIGENICITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG DELIVERY SYSTEM; HUMAN IMMUNODEFICIENCY VIRUS 1; INTERNALIZATION; MACROPHAGE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN STABILITY; SUSTAINED DRUG RELEASE; UPREGULATION; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMISTRY; IMMUNOLOGY; METABOLISM;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; ANIMALS; ANTIGENS, CD40; CARBOHYDRATES; CELLS, CULTURED; DENDRITIC CELLS; HIV ENVELOPE PROTEIN GP41; HIV-1; INTERLEUKIN-6; LECTINS, C-TYPE; MANNOSE-BINDING LECTINS; MICE, INBRED C57BL; NANOPARTICLES; POLYANHYDRIDES; RECEPTORS, CELL SURFACE; TUMOR NECROSIS FACTOR-ALPHA; VACCINES, SYNTHETIC;

EID: 84906321788     PISSN: 09205063     EISSN: 15685624     Source Type: Journal    
DOI: 10.1080/09205063.2014.940243     Document Type: Article

References (76)

1. Geijtenbeek TB, Gringhuis SI. Signalling through C-type lectin receptors: shaping immune responses. Nat. Rev. Immunol. 2009; 9: 465-479
2. Keler T, Ramakrishna V, Fanger MW. Mannose receptor-targeted vaccines. Expert Opin. Biol. Ther. 2004; 4: 1953-1962
3. Irache JM, Salman HH, Gamazo C, Espuelas S. Mannose-targeted systems for the delivery of therapeutics. Expert Opin. Drug Deliv. 2008; 5: 703-724
4. Deng Z, Li S, Jiang X, Narain R. Well-defined galactose-containing multi-functional copolymers and glyconanoparticles for biomolecular recognition processes. Macromolecules. 2009; 42: 6393-6405
5. Song EH, Osanya AO, Petersen CA, Pohl NL. Synthesis of multivalent tuberculosis and Leishmania-Associated capping carbohydrates reveals structure-dependent responses allowing immune evasion. J. Am. Chem. Soc. 2010; 132: 11428-11430
6. Engering AJ, Cella M, Fluitsma D, Brockhaus M, Hoefsmit EC, Lanzavecchia A, Pieters J. The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur. J. Immunol. 1997; 27: 2417-2425
7. Upham JP, Pickett D, Irimura T, Anders EM, Reading PC. Macrophage receptors for influenza A virus: role of the macrophage galactose-type lectin and mannose receptor in viral entry. J. Virol. 2010; 84: 3730-3737
8. Jiang HL, Kang ML, Quan JS, Kang SG, Akaike T, Yoo HS, Cho CS. The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization. Biomaterials. 2008; 29: 1931-1939
9. Figdor CG, van Kooyk Y, Adema GJ. C-type lectin receptors on dendritic cells and Langerhans cells. Nat. Rev. Immunol. 2002; 2: 77-84
10. Cambi A, Figdor CG. Dual function of C-type lectin-like receptors in the immune system. Curr. Opin. Cell Biol. 2003; 15: 539-546
11. Stahl PD. The mannose receptor and other macrophage lectins. Curr. Opin. Immunol. 1992; 4: 49-52-7915(92)90123-V
12. Pyż E, Marshall AS, Gordon S, Brown GD. C-type lectin-like receptors on myeloid cells. Ann. Med. 2006; 38: 242-251
13. Chehimi J, Luo Q, Azzoni L, Shawver L, Ngoubilly N, June R, Jerandi G, Farabaugh M, Montaner LJ. HIV-1 transmission and cytokine-induced expression of DC-SIGN in human monocyte-derived macrophages. J. Leukoc. Biol. 2003; 74: 757-763
14. Herbein G, Gras G, Khan KA, Abbas W. Macrophage signaling in HIV-1 infection. Retrovirology. 2010; 7: 34
15. Gringhuis SI, van der Vlist M, van den Berg LM, den Dunnen J, Litjens M, Geijtenbeek TB. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat. Immunol. 2010; 11: 419-426
16. Mascola JR, Montefiori DC. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010; 28: 413-444
17. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol. 2004; 4: 199-210
18. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. Geneva: United Nations; 2010.
19. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 2010; 10: 11-23
20. Catalfamo M, Di Mascio M, Hu Z, Srinivasula S, Thaker V, Adelsberger J, Rupert A, Baseler M, Tagaya Y, Roby G, Rehm C, Follmann D, Lane HC. HIV infection-Associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc. Natl. Acad. Sci. U.S.A. 2008; 105: 19851-19856
21. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Microbiol. 2008; 6: 143-155.
22. Nguyen DG, Hildreth JE. Involvement of macrophage mannose receptor in the binding and transmission of HIV by macrophages. Eur. J. Immunol. 2003; 33: 483-493
23. Sol-Foulon N, Moris A, Nobile C, Boccaccio C, Engering A, Abastado JP, Heard JM, van Kooyk Y, Schwartz O. HIV-1 NEF-induced upregulation of DC-SIGN in dendritic cells promotes lymphocyte clustering and viral spread. Immunity. 2002; 16: 145-155
24. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, Figdor CG, van Kooyk Y. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell. 2000; 100: 587-597
25. Chung NP, Matthews K, Klasse PJ, Sanders RW, Moore JP. HIV-1 gp120 impairs the induction of B cell responses by TLR9-Activated plasmacytoid dendritic cells. J. Immunol. 2012; 189: 5257-5265.
26. Scanlan CN, Offer J, Zitzmann N, Dwek RA. Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature. 2007; 446: 1038-1045
27. Shi W, Bohon J, Han DP, Habte H, Qin Y, Cho MW, Chance MR. Structural characterization of HIV gp41 with the membrane-proximal external region. J. Biol. Chem. 2010; 285: 24290-24298
28. Conix A. Poly[1,3-bis(p -carboxyphenoxy)-propane anhydride]. Macromol. Synth. 1966; 2: 95-98.
29. Kumar N, Langer RS, Domb AJ. Polyanhydrides: An overview. Adv. Drug Deliv. Rev. 2002; 54: 889-910
30. Torres MP, Vogel BM, Narasimhan B, Mallapragada SK. Synthesis and characterization of novel polyanhydrides with tailored erosion mechanisms. J. Biomed. Mater. Res. A. 2006; 76A: 102-110
31. Petersen LK, Sackett CK, Narasimhan B. High-throughput analysis of protein stability in polyanhydride nanoparticles. Acta Biomater. 2010; 6: 3873-3881
32. Carrillo-Conde B, Schiltz E, Yu J, Chris Minion F, Phillips GJ, Wannemuehler MJ, Narasimhan B. Encapsulation into amphiphilic polyanhydride microparticles stabilizes Yersinia pestis antigens. Acta Biomater. 2010; 6: 3110-3119
33. Ulery BD, Kumar D, Ramer-Tait AE, Metzger DW, Wannemuehler MJ, Narasimhan B. Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases. PLoS One. 2011; 6: E17642. doi: 17610.11371/journal.pone.0017642
34. Kipper MJ, Wilson JH, Wannemuehler MJ, Narasimhan B. Single dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanism. J. Biomed Mater. Res. A. 2006; 76A: 798-810
35. Ulery BD, Petersen LK, Phanse Y, Kong CS, Broderick SR, Kumar D, Ramer-Tait AE, Carrillo-Conde B, Rajan K, Wannemuehler MJ, Bellaire BH, Metzger DW, Narasimhan B. Rational design of pathogen-mimicking amphiphilic materials as nanoadjuvants. Sci. Rep. 2011; 1: 198. doi: 10.1038/srep00198.
36. Penn-Nicholson A, Han DP, Kim SJ, Park H, Ansari R, Montefiori DC, Cho MW. Assessment of antibody responses against gp41 in HIV-1-infected patients using soluble gp41 fusion proteins and peptides derived from M group consensus envelope. Virology. 2008; 372: 442-456
37. Gaiha GD, Dong T, Palaniyar N, Mitchell DA, Reid KB, Clark HW. Surfactant protein A binds to HIV and inhibits direct infection of CD4+ cells, but enhances dendritic cell-mediated viral transfer. J. Immunol. 2008; 181: 601-609
38. Fantuzzi L, Canini I, Belardelli F, Gessani S. HIV-1 gp120 stimulates the production of beta-chemokines in human peripheral blood monocytes through a CD4-independent mechanism. J. Immunol. 2001; 166: 5381-5387
39. Shan M, Klasse PJ, Banerjee K, Dey AK, Iyer SP, Dionisio R, Charles D, Campbell-Gardener L, Olson WC, Sanders RW, Moore JP. HIV-1 gp120 mannoses induce immunosuppressive responses from dendritic cells. PLoS Pathog. 2007; 3: E169
40. Shen E, Pizsczek R, Dziadul B, Narasimhan B. Microphase separation in bioerodible copolymers for drug delivery. Biomaterials. 2001; 22: 201-210 -9612(00)00175-7
41. Torres MP, Wilson-Welder JH, Lopac SK, Phanse Y, Carrillo-Conde B, Ramer-Tait AE, Bellaire BH, Wannemuehler MJ, Narasimhan B. Polyanhydride microparticles enhance dendritic cell antigen presentation and activation. Acta Biomater. 2011; 7: 2857-2864
42. Kipper MJ, Shen E, Determan A, Narasimhan B. Design of an injectable system based on bioerodible polyanhydride microspheres for sustained drug delivery. Biomaterials. 2002; 23: 4405-4412
43. Ulery BD, Phanse Y, Sinha A, Wannemuehler MJ, Narasimhan B, Bellaire BH. Polymer chemistry influences monocytic uptake of polyanhydride nanospheres. Pharm. Res. 2009; 26: 683-690
44. Jaipuri FA, Pohl NL. Toward solution-phase automated iterative synthesis: Fluorous-tag assisted solution-phase synthesis of linear and branched mannose oligomers. Org. Biomol. Chem. 2008; 6: 2686-2691
45. Curran DP, Luo Z. Fluorous synthesis with fewer fluorines (light fluorous synthesis): separation of tagged from untagged products by solid-phase extraction with fluorous reverse-phase silica gel. J. Am. Chem. Soc. 1999; 121: 9069-9072
46. Zhang W. Fluorous linker-facilitated chemical synthesis. Chem. Rev. 2009; 109: 749-795
47. Zhang W, Curran DP. Synthetic applications of fluorous solid-phase extraction (F-SPE). Tetrahedron. 2006; 62: 11837-11865
48. Carrillo-Conde B, Song EH, Chavez-Santoscoy A, Phanse Y, Ramer-Tait AE, Pohl NL, Wannemuehler MJ, Bellaire BH, Narasimhan B. Mannose-functionalized "pathogen-like" polyanhydride nanoparticles target C-type lectin receptors on dendritic cells. Mol. Pharm. 2011; 8: 1877-1886
49. Chavez-Santoscoy AV, Roychoudhury R, Pohl NL, Wannemuehler MJ, Narasimhan B, Ramer-Tait AE. Tailoring the immune response by targeting C-type lectin receptors on alveolar macrophages using pathogen-like amphiphilic polyanhydride nanoparticles. Biomaterials. 2012; 33: 4762-4772
50. Carrillo-Conde BR, Roychoudhury R, Chavez-Santoscoy AV, Narasimhan B, Pohl NL. High-throughput synthesis of carbohydrates and functionalization of polyanhydride nanoparticles. J. Vis. Exp. 2012; 64: E3884. doi: 10.3791/3884.
51. Phanse Y, Carrillo-Conde BR, Ramer-Tait AE, Roychoudhury R, Pohl NL, Narasimhan B, Wannemuehler MJ, Bellaire BH. Functionalization of polyanhydride microparticles with di-mannose influences uptake by and intracellular fate within dendritic cells. Acta Biomater. 2013; 9: 8902-8909
52. Masuko T, Minami A, Iwasaki N, Majima T, Nishimura S, Lee YC. Carbohydrate analysis by a phenol-sulfuric acid method in microplate format. Anal. Biochem. 2005; 339: 69-72
53. Lopac SK, Torres MP, Wilson-Welder JH, Wannemuehler MJ, Narasimhan B. Effect of polymer chemistry and fabrication method on protein release and stability from polyanhydride microspheres. J. Biomed. Mater. Res. B Appl. Biomater. 2009; 91B: 938-947
54. Torres MP, Determan AS, Anderson GL, Mallapragada SK, Narasimhan B. Amphiphilic polyanhydrides for protein stabilization and release. Biomaterials. 2007; 28: 108-116
55. Carrillo-Conde BR, Ramer-Tait AE, Wannemuehler MJ, Narasimhan B. Chemistry-dependent adsorption of serum proteins onto polyanhydride microparticles differentially influences dendritic cell uptake and activation. Acta Biomater. 2012; 8: 3618-3628
56. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Purtscher M, Gruber G, Tauer C, Steindl F, Jungbauer A, Katinger H. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retroviruses. 1994; 10: 359-369
57. Purtscher M, Trkola A, Grassauer A, Schulz PM, Klima A, Döpper S, Gruber G, Buchacher A, Muster T, Katinger H. Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. AIDS. 1996; 10: 587-593
58. Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, Steindl F, Tauer C, Berger R, Barrett N, Jungbauer A, Katinger H. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses. 1994; 10: 1651-1658
59. Nelson JD, Brunel FM, Jensen R, Crooks ET, Cardoso RM, Wang M, Hessell A, Wilson IA, Binley JM, Dawson PE, Burton DR, Zwick MB. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J. Virol. 2007; 81: 4033-4043
60. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, Katinger H. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses. 2001; 17: 1757-1765
61. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PW. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 2001; 75: 10892-10905
62. Petersen LK, Xue L, Wannemuehler MJ, Rajan K, Narasimhan B. The simultaneous effect of polymer chemistry and device geometry on the in vitro activation of murine dendritic cells. Biomaterials. 2009; 30: 5131-5142
63. Petersen LK, Ramer-Tait AE, Broderick SR, Kong CS, Ulery BD, Rajan K, Wannemuehler MJ, Narasimhan B. Activation of innate immune responses in a pathogen-mimicking manner by amphiphilic polyanhydride nanoparticle adjuvants. Biomaterials. 2011; 32: 6815-6822
64. Determan AS, Graham JR, Pfeiffer KA, Narasimhan B. The role of microsphere fabrication methods on the stability and release kinetics of ovalbumin encapsulated in polyanhydride microspheres. J. Microencapsul. 2006; 23: 832-843
65. Petersen LK, Phanse Y, Ramer-Tait AE, Wannemuehler MJ, Narasimhan B. Amphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigen. Mol. Pharm. 2012; 9: 874-882
66. Adams EW, Ratner DM, Seeberger PH, Hacohen N. Carbohydrate-mediated targeting of antigen to dendritic cells leads to enhanced presentation of antigen to T cells. Chembiochem. 2008; 9: 294-303
67. Turville S, Wilkinson J, Cameron P, Dable J, Cunningham AL. The role of dendritic cell C-type lectin receptors in HIV pathogenesis. J. Leukoc. Biol. 2003; 74: 710-718
68. Berzi A, Varga N, Sattin S, Antonazzo P, Biasin M, Cetin I, Trabattoni D, Bernardi A, Clerici M. Pseudo-mannosylated DC-SIGN ligands as potential adjuvants for HIV vaccines. Viruses. 2014; 6: 391-403
69. Jameson B, Baribaud F, Pohlmann S, Ghavimi D, Mortari F, Doms RW, Iwasaki A. Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques. J. Virol. 2002; 76: 1866-1875
70. Cunningham AL, Harman AN, Donaghy H. DC-SIGN AIDS HIV immune evasion and infection. Nat. Immunol. 2007; 8: 556-558
71. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med. 2005; 11: S45-S53
72. Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev. 2009; 229: 152-172
73. McKenzie EJ, Taylor PR, Stillion RJ, Lucas AD, Harris J, Gordon S, Martinez-Pomares L. Mannose receptor expression and function define a new population of murine dendritic cells. J. Immunol. 2007; 178: 4975-4983
74. Ohtani M, Iyori M, Saeki A, Tanizume N, Into T, Hasebe A, Totsuka Y, Shibata K. Involvement of suppressor of cytokine signalling-1-mediated degradation of MyD88-Adaptor-like protein in the suppression of Toll-like receptor 2-mediated signalling by the murine C-type lectin SIGNR1-mediated signalling. Cell. Microbiol. 2012; 14: 40-57
75. Lewis JS, Zaveri TD, Crooks CP 2nd, Keselowsky BG. Microparticle surface modifications targeting dendritic cells for non-Activating applications. Biomaterials. 2012; 33: 7221-7232
76. Saunders SP, Barlow JL, Walsh CM, Bellsoi A, Smith P, McKenzie AN, Fallon PG. C-type lectin SIGN-R1 has a role in experimental colitis and responsiveness to lipopolysaccharide. J. Immunol. 2010; 184: 2627-2637